Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

References

• Acharya M, Gonzalez M, Mannens G, et al. (2013). A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica 43:379–389.
   PubMed Web of Science ®Google Scholar
• Arjomand A. (2010). Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis 2:519–541.
   PubMed Web of Science ®Google Scholar
• Bae SK, Shon JH. (2011). Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials. Arch Pharm Res 34:1789–1798.
   PubMed Web of Science ®Google Scholar
• Ballard P, Swaisland HC, Malone MD, et al. (2014). Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. Xenobiotica 44:1083–1098.
   PubMed Web of Science ®Google Scholar
• Becker A, von Richter O, Kovar A, et al. (2015). Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans. J Clin Pharmacol 55:815–824.
   PubMed Web of Science ®Google Scholar
• Bello CL, Smith E, Ruiz-Garcia A, et al. (2013). A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol 72:379–385.
   PubMed Web of Science ®Google Scholar
• Bershas DA, Ouellet D, Mamaril-Fishman DB, et al. (2013). Metabolism and disposition of oral dabrafenib in cancer patients: Proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation. Drug Metab Dispos 41:2215–2224.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Beijnen JH, Schellens JH. (2006). Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33–58.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. (2005). Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 23:429–436.
   PubMed Web of Science ®Google Scholar
• Brown K, Dingley KH, Turteltaub KW. (2005). Accelerator mass spectrometry for biomedical research. Meth Enzymol 402:423–443.
   PubMed Web of Science ®Google Scholar
• Castellino S, O’Mara M, Koch K, et al. (2012). Human metabolism of lapatinib, a dual kinase inhibitor: Implications for hepatotoxicity. Drug Metab Dispos 40:139–150.
   PubMed Web of Science ®Google Scholar
• Chen N, Wen L, Lau H, et al. (2012). Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 69:789–797.
   PubMed Web of Science ®Google Scholar
• Christopher LJ, Hong H, Vakkalagadda BJ, et al. (2010). Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. Drug Metab Dispos 38:2049–2059.
   PubMed Web of Science ®Google Scholar
• Clive S, Woo MM, Nydam T, et al. (2012). Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70:513–522.
   PubMed Web of Science ®Google Scholar
• Dennis M, Davies M, Oliver S, et al. (2012). Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol 70:461–469.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Nijenhuis CM, Jansen RS, et al. (2016). Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: A cross-species comparison. Invest New Drugs [Epub ahead of print]. doi: 10.1007/s10637-016-0342-y.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Darwish M, et al. (2013). Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D 13:17–28.
   PubMedGoogle Scholar
• Dubbelman AC, Rosing H, Jansen RS, et al. (2012a). Mass balance study of [14C]eribulin in patients with advanced solid tumors. Drug Metab Dispos 40:313–321.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Nijenhuis C, et al. (2015). Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs 33:233–240.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Upthagrove A, Beijnen JH, et al. (2012b). Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol 70:653–663.
   PubMed Web of Science ®Google Scholar
• European Agency for Safety and Health at Work (EASHW). (2013). Directive 2013/59/Euratom – Protection against ionising radiation. Available from: https://osha.europa.eu/en/legislation/directives/directive-2013-59-euratom-protection-against-ionising-radiation [last accessed 6 January 2016].
   Google Scholar
• European Agency for Safety and Health at Work (EASHW). (2015). Directive 96/29/Euratom – Ionizing radiation. Available from: https://osha.europa.eu/en/legislation/directives/73. [last accessed 6 January 2016].
   Google Scholar
• European Medicines Agency (EMA). (1987). Pharmacokinetic studies in man. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003127.pdf [last accessed 6 January 2016].
   Google Scholar
• European Medicines Agency (EMA). (2007). Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins, Committee for medicinal products for human use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029.pdf [last accessed 6 January 2016].
   Google Scholar
• European Medicines Agency (EMA). (2013a). Guideline on the evaluation of anticancer medicinal products in man, Oncology Working Party. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf [last accessed 6 January 2016].
   Google Scholar
• European Medicines Agency (EMA). (2013b). Guideline on the investigation of drug interactions, Committee for Human Medicinal Products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 6 January 2016].
   Google Scholar
• Garner RC. (2010). Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429–440.
   PubMed Web of Science ®Google Scholar
• Garner RC, Barker J, Flavell C, et al. (2000). A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197–209.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, Ouatas T, Krauwinkel W, et al. (2015). Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet 54:1043–1055.
   PubMed Web of Science ®Google Scholar
• Gilman SD, Gee SJ, Hammock BD, et al. (1998). Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal Chem 70:3463–3469.
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Rinderknecht J, Dummer R, et al. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect 3:e00113.
   PubMedGoogle Scholar
• Graham RA, Lum BL, Morrison G, et al. (2011). A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 39:1460–1467.
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F, et al. (2005). Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503–1512.
   PubMed Web of Science ®Google Scholar
• Hah SS, Henderson PT, Turteltaub KW. (2009). Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci 16:54.
   PubMed Web of Science ®Google Scholar
• Ho MY, Morris MJ, Pirhalla JL, et al. (2014). Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica 44:352–368.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kasserra C, Reyes J, et al. (2013). Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 71:489–501.
   PubMed Web of Science ®Google Scholar
• Holden SN, Eckhardt SG, Basser R, et al. (2005). Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391–1397.
   PubMed Web of Science ®Google Scholar
• International Commission on Radiological Protection (ICRP). (1992). ICRP Publication 62: Radiological Protection in Biomedical Research, Ann. ICRP 22 (3). Available from: http://ani.sagepub.com/content/suppl/2013/06/25/22.3.DC1/P_062_JAICRP_22_3_Radiological_Protection_in_Biomedical_Research.pdf [last accessed 6 January 2016].
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2010). S9 Nonclinical Evaluation for anticancer pharmaceuticals. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm085389.pdf [last accessed 6 January 2016].
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2013a). M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM292164.pdf [last accessed 6 January 2016].
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2013b). M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, questions and answers (R2). Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM292164.pdf [last accessed 6 January 2016].
   Google Scholar
• Inoue K, Asai N, Mizuo H, et al. (2012). Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey. Drug Metab Dispos 40:662–670.
   PubMed Web of Science ®Google Scholar
• James A, Blumenstein L, Glaenzel U, et al. (2015). Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemother Pharmacol 76:751–760.
   PubMed Web of Science ®Google Scholar
• Johnson TR, Tan W, Goulet L, et al. (2015). Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 45:45–59.
   PubMed Web of Science ®Google Scholar
• Keck BD, Ognibene T, Vogel JS. (2010). Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2:469–485.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Zollinger M, Lozac’h F, et al. (2013). Metabolism of patupilone in patients with advanced solid tumor malignancies. Invest New Drugs 31:605–615.
   PubMed Web of Science ®Google Scholar
• Lacy S, Hsu B, Miles D, et al. (2015). Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos 43:1190–1207.
   PubMed Web of Science ®Google Scholar
• Lappin G. (2016). Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers. J Clin Pharmacol 56:11–23.
   PubMed Web of Science ®Google Scholar
• Lappin G, Stevens L. (2008). Biomedical accelerator mass spectrometry: Recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 4:1021–1033.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Seraj J, Yoshida K, et al. (2016). Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol 77:515–526.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449.
   PubMed Web of Science ®Google Scholar
• Ling J, Johnson KA, Miao Z, et al. (2006). Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420–426.
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Kennedy SJ, et al. (2012). Pharmacokinetics of vandetanib: Three phase I studies in healthy subjects. Clin Ther 34:221–237.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Fong PC, Hong X, et al. (2012). Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial. Cancer Chemother Pharmacol 69:1145–1154.
   PubMed Web of Science ®Google Scholar
• McKillop D, Hutchison M, Partridge EA, et al. (2004). Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34:917–934.
   PubMed Web of Science ®Google Scholar
• Mekhail T, Masson E, Fischer BS, et al. (2010). Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos 38:1962–1966.
   PubMed Web of Science ®Google Scholar
• Murai T, Takakusa H, Nakai D, et al. (2014). Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica 44:996–1008.
   PubMed Web of Science ®Google Scholar
• Nijenhuis CM, Lucas L, Rosing H, et al. (2016). Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2016.1152418.
   PubMed Web of Science ®Google Scholar
• Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203.
   PubMed Web of Science ®Google Scholar
• Penner N, Xu L, Prakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513–531.
   PubMed Web of Science ®Google Scholar
• Prakash C, Shaffer CL, Tremaine LM, et al. (2007). Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab Lett 1:226–231.
   PubMedGoogle Scholar
• Ridoux L, Semiond DR, Vincent C, et al. (2015). A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anticancer Drugs 26:350–358.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
   PubMed Web of Science ®Google Scholar
• Shilling AD, Nedza FM, Emm T, et al. (2010). Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 38:2023–2031.
   PubMed Web of Science ®Google Scholar
• Smith BJ, Pithavala Y, Bu HZ, et al. (2014). Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos 42:918–931.
   PubMed Web of Science ®Google Scholar
• Solon E. (2010). Predicting human radiation dosimetry for clinical radiolabeled drug development studies: A comparison of methods. J Label Compd Radiopharm 53:283–287.
   Web of Science ®Google Scholar
• Speed B, Bu HZ, Pool WF, et al. (2012). Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40:539–555.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Marzin K, Narjes H, et al. (2012). Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051–1061.
   PubMed Web of Science ®Google Scholar
• Swart P, Lozac’h F, Simon M, et al. (2016). The impact of early human data on clinical development: There is time to win. Drug Discov Today. [Epub ahead of print]. doi: 10.1016/j.drudis.2016.03.012.
   PubMed Web of Science ®Google Scholar
• Takahashi RH, Choo EF, Ma S, et al. (2016). Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]Cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos 44:28–39.
   PubMed Web of Science ®Google Scholar
• Tamura T, Minami H, Yamada Y, et al. (2006). A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1:1002–1009.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). (1987). Guidelines for the format and content of the human pharmacokinetics and bioavailability section of an application, Center for Drugs and Biologics, Food and Drug Administration, Department of Health and Human Services. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072112.pdf [last accessed 6 January 2016].
   Google Scholar
• US Food and Drug Administration (FDA). (2008). Guidance for industry: safety testing of drug metabolites, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf [last accessed 6 January 2016].
   Google Scholar
• US Food and Drug Administration (FDA). (2010). The Radioactive Drug Research Committee: human research without an investigational new drug application, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/UCM163892.pdf [last accessed 6 January 2016].
   Google Scholar
• US Food and Drug Administration (FDA). (2015). CFR 21 361: prescription drugs for human use generally recognized as safe and effective and not misbranded: Drugs used in research, Department of Health and Human Services. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR =361.1 [last accessed 6 January 2016].
   Google Scholar
• Wickremsinhe ER, Hynes SM, Palmieri MD, et al. (2014). Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica 44:827–841.
   PubMed Web of Science ®Google Scholar
• Widmer N, Bardin C, Chatelut E, et al. (2014). Review of therapeutic drug monitoring of anticancer drugs part two – targeted therapies. Eur J Cancer 50:2020–2036.
   PubMed Web of Science ®Google Scholar
• Young GC, Seymour M. (2015). Application of (14)C-accelerator MS in pharmaceutical development. Bioanalysis 7:513–517.
   PubMed Web of Science ®Google Scholar
• Yu H, Steeghs N, Nijenhuis CM, et al. (2014). Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets. Clin Pharmacokinet 53:305–325.
   PubMed Web of Science ®Google Scholar
• Zollinger M, Lozac’h F, Hurh E, et al. (2014). Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74:63–75.
   PubMed Web of Science ®Google Scholar